Expert Interview
A second look at the standard of care for Parkinson's Disease patients and the potential of Cerevel Therapeutics orally-administered, selective partial agonist of the dopamine D1 and D5 receptor, Tavapadon
Ticker(s): CEREDr. Laura Blanchard
- treats around 15 Myasthenia patients per month.
- has read several articles on the trials of Batoclimab.
- Neurology Nurse Practitioner with 7 years of experience in evaluating and treating patients with a wide variety of Neurological conditions, including but not limited to Alzheimers and other dementias, strokes, Epilepsy, Myasthenia Gravis, Multiple Sclerosis, Parkinson's disease, spinal radiculopathy, Migraines and other headaches, and Co-morbid Psychiatric disorders. Additionally, I have a background in Nursing Education. I am experienced with patient education, patient safety, and research. I enjoy consulting and contributing to my field.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
